![]() ![]() Level of evidenceīinge eating disorder (BED) is characterized by the recurrent consumption of an amount of food within a discrete period that is larger than what most people would eat, by a lack of control, and by marked distress over binge eating (BE). Furthermore, these data indicate that pharmacologic and nonpharmacologic treatment for BED is associated with decreased binge eating and improvements in overall well-being. Although HCPs are initiating discussions about BED, earlier identification of BED symptoms is required. These findings highlight the importance of timely diagnosis and treatment of BED. 3.5 ± 6.0) Across pharmacotherapies and nonpharmacotherapies, most patients reported improvement in symptoms of BED (84–97%) and in overall well-being (80–96%). The mean ± SD number of binge eating episodes/week numerically decreased from pretreatment to follow-up with lisdexamfetamine (5.4 ± 2.8 vs. A numerically greater percentage of patients received (past or current) nonpharmacotherapy than pharmacotherapy (84% vs. Most patients (64%) received a diagnosis of BED ≥ 3 years after symptom onset. Discussions regarding a diagnosis of BED were typically initiated more often by HCPs than patients. Comorbidities identified in > 20% of patients included obesity (50%), anxiety (49%), depression and/or major depressive disorder (46%), and dyslipidemia (26%). Most patients were women (69%) and white (78%). Overall, 202 charts from 57 healthcare providers (HCPs) were reviewed. This retrospective chart review examined the clinical characteristics, diagnostic pathways, and treatment history of adult patients diagnosed with BED. In the Canadian healthcare setting, there is limited understanding of the pathways to diagnosis and treatment for patients with binge eating disorder (BED). ![]()
0 Comments
Leave a Reply. |